Genpact Named One of Newsweek's America's Greatest Workplaces for Parents & Families 2026
Get Alerts G Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.2%
Revenue Growth %: +7.0%
Join SI Premium – FREE
Recognition highlights Genpact's continued focus on building an inclusive workplace that supports employees across work and family life
"This recognition reflects the importance we place on creating an environment where our people can succeed in all dimensions of their lives," said
The list, compiled by Newsweek in partnership with Plant-A Insights Group, recognizes
Genpact's support for working parents and caregivers includes competitive paid parental leave, flexible work options such as hybrid schedules and adjustable hours, well-being resources, and leadership accountability for building inclusive team environments where employees can contribute and grow.
About Genpact
Genpact (NYSE: G) is the Agentic Operations company, where applied AI meets context-rich process intelligence. We run and transform mission-critical operations for global enterprises. Genpact's Agentic Operations are grounded in decades of operating core business processes at scale across finance, supply chain, banking, insurance, and more. Our flywheel of advanced technology, trusted data foundations, and deep ecosystem partnerships moves enterprises rapidly from experimentation to scale. AI agents bring speed and precision, human experts bring judgment, and together they deliver outcomes clients can measure.
Get to know us at genpact.com and on LinkedIn, YouTube, X, and Facebook.
MEDIA CONTACT:
Keith Gordon
Genpact Media Relations
+1-917-204-9952
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/genpact-named-one-of-newsweeks-americas-greatest-workplaces-for-parents--families-2026-302868505.html
SOURCE Genpact
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Beactica Therapeutics initiates IND-enabling studies for BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma
- ZEX PR WIRE Heads to Seamless Middle East 2026 as the Region's Fintech, Payments and Commerce Leaders Converge in Dubai
- AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share